Abstract
Ghrelin, a small peptide hormone (28 aa), secreted mainly by X/A-like cells of gastric mucosa, is also locally produced in cardiomyocytes. Being an orexigenic factor (appetite stimulant), it promotes release of growth hormone (GH) and exerts diverse physiological functions, viz. regulation of energy balance, glucose, and/or fat metabolism for body weight maintenance. Interestingly, administration of exogenous ghrelin significantly improves cardiac functions in CVD patients as well as experimental animal models of heart failure. Ghrelin ameliorates pathophysiological condition of the heart in myocardial infarction, cardiac hypertrophy, fibrosis, cachexia, and ischemia reperfusion injury. This peptide also exerts significant impact at the level of vasculature leading to lowering high blood pressure and reversal of endothelial dysfunction and atherosclerosis. However, the molecular mechanism of actions elucidating the healing effects of ghrelin on the cardiovascular system is still a matter of conjecture. Some experimental data indicate its beneficial effects via complex cellular cross talks between autonomic nervous system and cardiovascular cells, some other suggest more direct receptor–mediated molecular actions via autophagy or ionotropic regulation and interfering with apoptotic and inflammatory pathways of cardiomyocytes and vascular endothelial cells. Here, in this review, we summarise available recent data to encourage more research to find the missing links of unknown ghrelin receptor–mediated pathways as we see ghrelin as a future novel therapy in cardiovascular protection.
Similar content being viewed by others
References
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656–660
Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, Suganuma T, Matsukura S, Kangawa K, Nakazato M (2000) Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141:4255–4261
Ghelardoni S, Carnicelli V, Frascarelli S, Ronca-Testoni S, Zucchi R (2006) Ghrelin tissue distribution: comparison between gene and protein expression. J Endocrinol Investig 29:115–121
Tokudome T, Otani K, Miyazato M, Kangawa K (2019) Ghrelin and the heart. Peptides 111:42–46
Muller TD, Nogueiras R, Andermann ML, Andrews ZB, Anker SD, Argente J, Batterham RL, Benoit SC, Bowers CY, Broglio F, Casanueva FF, DAlessio D, Depoortere I, Geliebter A, Ghigo E, Cole PA, Cowley M, Cummings DE, Dagher A, Diano S et al (2015) Ghrelin. Mol Metab 4:437–460
Yang J, Brown MS, Liang G, Grishin NV, Goldstein JL (2008) Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell 132:387–396
Murtuza MI, Isokawa M (2018) Endogenous ghrelin-O-acyltransferase (GOAT) acylates local ghrelin in the hippocampus. J Neurochem 144:58–67
Davenport AP, Bonner TI, Foord SM, Harmar AJ, Neubig RR, Pin JP, Spedding M, Kojima M, Kangawa K (2005) International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function. Pharmacol Rev 57:541–546
Ikenoya C, Takemi S, Kaminoda A, Aizawa S, Ojima S, Gong Z, Chacrabati R, Kondo D, Wada R, Tanaka T, Tsuda S, Sakai T, Sakata I (2018) β-Oxidation in ghrelin-producing cells is important for ghrelin acyl-modification. Sci Rep 8:9176
Rusu CC, Racasan S, Moldovan D, Potra A, Tirinescu D, Budurea C, Orasan R, Patiu IM, Bondor C, Vladutiu D, Delean D, Danu A, Kacso IM (2018) Ghrelin and acyl ghrelin levels are associated with inflammatory and nutritional markers and with cardiac and vascular dysfunction parameters in hemodialysis patients. Int Urol Nephrol 50:1897–1906
Andrews ZB (2019) The next big LEAP2 understanding ghrelin function. J Clin Invest 129:3542–3544
Ogawa T, de Bold AJ (2014) The heart as an endocrine organ. Endocr Connect 3:31–44
Glembotski CC (2011) Functions for the cardiomyokine, MANF, in cardioprotection, hypertrophy and heart failure. J Mol Cell Cardiol 51:512–517
Sullivan R, McGirr R, Hu S, Tan A, Wu D, Charron C, Lalonde T, Arany E, Chakrabarti S, Luyt L, Dhanvantari S (2018) Changes in the cardiac GHSR1a-ghrelin system correlate with myocardial dysfunction in diabetic cardiomyopathy in mice. J Endocr Soc 2:178–189
Yuan MJ, Wang T, Kong B, Wang X, Huang CX, Wang D (2016) GHSR-1a is a novel pro-angiogenic and anti-remodeling target in rats after myocardial infarction. Eur J Pharmacol 788:218–225
Celik O, Celik N, Aydin S, Aygun BK, Haberal ET, Kuloglu T, Ulas M, Aktun LH, Acet M, Celik S (2016) Ghrelin action on GnRH neurons and pituitary gonadotropes might be mediated by GnIH-GPR147 system. Horm Mol Biol Clin Investig, vol 25:121–128
Thompson NM, Gill DA, Davies R, Loveridge N, Houston PA, Robinson IC, Wells T (2004) Ghrelin and des-octanoyl ghrelin promote adipogenesis directly in vivo by a mechanism independent of the type 1a growth hormone secretagogue receptor. Endocrinology 145:234–242
Lilleness BM, Frishman WH (2016) Ghrelin and the cardiovascular system. Cardiol Rev 24:288–297
Seim I, Jeffery PL, Thomas PB, Walpole CM, Maugham M, Fung JN, Yap PY, OKeeffe AJ, Lai J, Whiteside EJ, Herington AC, Chopin LK (2016) Multi-species sequence comparison reveals conservation of ghrelin gene-derived splice variants encoding a truncated ghrelin peptide. Endocrine 52:609–617
Delporte C (2013) Structure and physiological actions of ghrelin. Scientifica (Cairo) 2013:518909
Zhu X, Cao Y, Voogd K, Voodg K, Steiner DF (2006) On the processing of proghrelin to ghrelin. J Biol Chem 281:38867–38870
Gutierrez JA, Solenberg PJ, Perkins DR, Willency JA, Knierman MD, Jin Z, Witcher DR, Luo S, Onyia JE, Hale JE (2008) Ghrelin octanoylation mediated by an orphan lipid transferase. Proc Natl Acad Sci U S A 105:6320–6325
Delhanty PJ, Neggers SJ, van der Lely AJ (2013) Des-acyl ghrelin: a metabolically active peptide. Endocr Dev 25:112–121
Hosoda H, Kojima M, Mizushima T, Shimizu S, Kangawa K (2003) Structural divergence of human ghrelin. Identification of multiple ghrelin-derived molecules produced by post-translational processing. J Biol Chem 278:64–70
Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, Paress PS, Diaz C, Chou M, Liu KK, McKee KK, Pong SS, Chaung LY, Elbrecht A, Dashkevicz M, Heavens R et al (1996) A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273:974–977
Wierup N, Sundler F, Heller RS (2014) The islet ghrelin cell. J Mol Endocrinol 52:35–49
Camina JP (2006) Cell biology of the ghrelin receptor. J Neuroendocrinol 18:65–76
Callaghan B, Furness JB (2014) Novel and conventional receptors for ghrelin, desacyl-ghrelin, and pharmacologically related compounds. Pharmacol Rev 66:984–1001
Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoni S, Fubini A, Malan D, Baj G, Granata R, Broglio F, Papotti M, Surico N, Bussolino F, Isgaard J, Deghenghi R, Sinigaglia F, Prat M, Muccioli G, Ghigo E, Graziani A (2002) Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol 159:1029–1037
Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P, Bhattacharya S, Carpenter R, Grossman AB, Korbonits M (2002) The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 87:2988
Leung PK, Chow KB, Lau PN, Chu KM, Chan CB, Cheng CH, Wise H (2007) The truncated ghrelin receptor polypeptide (GHS-R1b) acts as a dominant-negative mutant of the ghrelin receptor. Cell Signal 19:1011–1022
Bednarek MA, Feighner SD, Pong SS, McKee KK, Hreniuk DL, Silva MV, Warren VA, Howard AD, Van Der Ploeg LH, Heck JV (2000) Structure-function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a. J Med Chem 43:4370–4376
Toshinai K, Yamaguchi H, Sun Y, Smith RG, Yamanaka A, Sakurai T, Date Y, Mondal MS, Shimbara T, Kawagoe T, Murakami N, Miyazato M, Kangawa K, Nakazato M (2006) Des-acyl ghrelin induces food intake by a mechanism independent of the growth hormone secretagogue receptor. Endocrinology 147:2306–2314
Bodart V, Bouchard JF, McNicoll N, Escher E, Carriere P, Ghigo E, Sejlitz T, Sirois MG, Lamontagne D, Ong H (1999) Identification and characterization of a new growth hormone-releasing peptide receptor in the heart. Circ Res 85:796–802
Muccioli G, Broglio F, Valetto MR, Ghe C, Catapano F, Graziani A, Papotti M, Bisi G, Deghenghi R, Ghigo E (2000) Growth hormone-releasing peptides and the cardiovascular system. Ann Endocrinol (Paris) 61:27–31
Papotti M, Ghe C, Cassoni P, Catapano F, Deghenghi R, Ghigo E, Muccioli G (2000) Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab 85:3803–3807
Cao JM, Ong H, Chen C (2006) Effects of ghrelin and synthetic GH secretagogues on the cardiovascular system. Trends Endocrinol Metab 17:13–18
Beiras-Fernandez A, Kreth S, Weis F, Ledderose C, Pöttinger T, Dieguez C, Beiras A, Reichart B (2010) Altered myocardial expression of ghrelin and its receptor (GHSR-1a) in patients with severe heart failure. Peptides 31:2222–2228
Lacerda-Miranda G, Soares VM, Vieira AK, Lessa JG, Rodrigues-Cunha AC, Cortez E, Garcia-Souza EP, Moura AS (2012) Ghrelin signaling in heart remodeling of adult obese mice. Peptides 35:65–73
Kleinz MJ, Maguire JJ, Skepper JN, Davenport AP (2006) Functional and immunocytochemical evidence for a role of ghrelin and des-octanoyl ghrelin in the regulation of vascular tone in man. Cardiovasc Res 69:227–235
Vestergaard ET, Andersen NH, Hansen TK, Rasmussen LM, Moller N, Sorensen KE, Sloth E, Jorgensen JO (2007) Cardiovascular effects of intravenous ghrelin infusion in healthy young men. Am J Physiol Heart Circ Physiol 293:H3020–H3026
Freeman JN, do Carmo JM, Adi AH, da Silva AA (2013) Chronic central ghrelin infusion reduces blood pressure and heart rate despite increasing appetite and promoting weight gain in normotensive and hypertensive rats. Peptides 42:35–42
Nagaya N, Uematsu M, Kojima M, Ikeda Y, Yoshihara F, Shimizu W, Hosoda H, Hirota Y, Ishida H, Mori H, Kangawa K (2001) Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 104:1430–1435
Soeki T, Kishimoto I, Schwenke DO, Tokudome T, Horio T, Yoshida M, Hosoda H, Kangawa K (2008) Ghrelin suppresses cardiac sympathetic activity and prevents early left ventricular remodeling in rats with myocardial infarction. Am J Physiol Heart Circ Physiol 294:H426–H432
Chang L, Ren Y, Liu X, Li WG, Yang J, Geng B, Weintraub NL, Tang C (2004) Protective effects of ghrelin on ischemia/reperfusion injury in the isolated rat heart. J Cardiovasc Pharmacol 43:165–170
Khatib MN, Shankar A, Kirubakaran R, Agho K, Simkhada P, Gaidhane S, Saxena DUB, Gode D, Gaidhane A, Zahiruddin SQ (2015) Effect of ghrelin on mortality and cardiovascular outcomes in experimental rat and mice models of heart failure: a systematic review and meta-analysis. PLoS One 10:e0126697
Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, Shimizu W, Ueno K, Kitakaze M, Miyatake K, Kangawa K (2004) Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 110:3674–3679
Lu L, Liu M, Sun R, Zheng Y, Zhang P (2015) Myocardial infarction: symptoms and treatments. Cell Biochem Biophys 72:865–867
Eid RA, Zaki MSA, Al-Shraim M, Eleawa SM, El-Kott AF, Al-Hashem FH, Eldeen MA, Ibrahim H, Aldera H, Alkhateeb MA (2018) Subacute ghrelin administration inhibits apoptosis and improves ultrastructural abnormalities in remote myocardium post-myocardial infarction. Biomed Pharmacother 101:920–928
Mao Y, Tokudome T, Otani K, Kishimoto I, Nakanishi M, Hosoda H, Miyazato M, Kangawa K (2012) Ghrelin prevents incidence of malignant arrhythmia after acute myocardial infarction through vagal afferent nerves. Endocrinology 153:3426–3434
Schwenke DO, Tokudome T, Kishimoto I, Horio T, Shirai M, Cragg PA, Kangawa K (2008) Early ghrelin treatment after myocardial infarction prevents an increase in cardiac sympathetic tone and reduces mortality. Endocrinology 149:5172–5176
Schwenke DO, Tokudome T, Kishimoto I, Horio T, Cragg PA, Shirai M, Kangawa K (2012) One dose of ghrelin prevents the acute and sustained increase in cardiac sympathetic tone after myocardial infarction. Endocrinology 153:2436–2443
Matsumoto M, Yasuda S, Miyazaki S, Kataoka Y, Hosoda H, Nagaya N, Noguchi T, Morii I, Ogawa H, Kangawa K (2013) Decreased serum ghrelin levels in patients with acute myocardial infarction. Tohoku J Exp Med 231:235–242
Gruzdeva O, Uchasova E, Belik E, Dyleva Y, Shurygina E, Barbarash O (2014) Lipid, adipokine and ghrelin levels in myocardial infarction patients with insulin resistance. BMC Cardiovasc Disord 14:7
Gruzdeva OV, Karetnikova VN, Akbasheva OE, Fedorova TS, Belik EV, Palicheva EI, Uchasova EG, Dyleva IUA, Brazovskaia NG, Barbarash OL (2013) Lipid, adipokine and ghrelin concentrations in myocardial infarction patients with insulin resistance. Vestn Akad Med Nauk SSSR:13–19
Mao Y, Tokudome T, Otani K, Kishimoto I, Miyazato M, Kangawa K (2013) Excessive sympathoactivation and deteriorated heart function after myocardial infarction in male ghrelin knockout mice. Endocrinology 154:1854–1863
Kondo H, Hojo Y, Takahashi N, Ikemoto T, Aoki H, Dezaki K, Kario K, Katsuki T, Yada T, Shimada K (2010) Roles of ghrelin in left-ventricular remodelling after acute myocardial infarction. Heart Asia 2:1–4
Chang L, Zhao J, Li GZ, Geng B, Pan CS, Qi YF, Tang CS (2004) Ghrelin protects myocardium from isoproterenol-induced injury in rats. Acta Pharmacol Sin 25:1131–1137
Ruozi G, Bortolotti F, Falcione A, Dal Ferro M, Ukovich L, Macedo A, Zentilin L, Filigheddu N, Gortan Cappellari G, Baldini G, Zweyer M, Barazzoni R, Graziani A, Zacchigna S, Giacca M (2015) AAV-mediated in vivo functional selection of tissue-protective factors against ischaemia. Nat Commun 6:7388
Huang CX, Yuan MJ, Huang H, Wu G, Liu Y, Yu SB, Li HT, Wang T (2009) Ghrelin inhibits post-infarct myocardial remodeling and improves cardiac function through anti-inflammation effect. Peptides 30:2286–2291
Yang C, Liu J, Liu K, Du B, Shi K, Ding M, Li B, Yang P (2018) Ghrelin suppresses cardiac fibrosis of post-myocardial infarction heart failure rats by adjusting the activin A-follistatin imbalance. Peptides 99:27–35
Wang Q, Sui X, Chen R, Ma PY, Teng YL, Ding T, Sui DJ, Yang P (2018) Ghrelin ameliorates angiotensin II-induced myocardial fibrosis by upregulating peroxisome proliferator-activated receptor gamma in Young male rats. Biomed Res Int 2018:9897581
Eid RA, Alkhateeb MA, Eleawa S, Al-Hashem FH, Al-Shraim M, El-Kott AF, Zaki MSA, Dallak MA, Aldera H (2018) Cardioprotective effect of ghrelin against myocardial infarction-induced left ventricular injury via inhibition of SOCS3 and activation of JAK2/STAT3 signaling. Basic Res Cardiol 113:13
Eid RA, Alkhateeb MA, Al-Shraim M, Eleawa SM, Shatoor AS, El-Kott AF, Zaki MSA, Shatoor KA, Bin-Jaliah I, Al-Hashem FH (2019) Ghrelin prevents cardiac cell apoptosis during cardiac remodelling post experimentally induced myocardial infarction in rats via activation of Raf-MEK1/2-ERK1/2 signalling. Arch Physiol Biochem 125:93–103
Wang Q, Lin P, Li P, Feng L, Ren Q, Xie X, Xu J (2017) Ghrelin protects the heart against ischemia/reperfusion injury via inhibition of TLR4/NLRP3 inflammasome pathway. Life Sci 186:50–58
Eid RA, El-Kott AF, Zaki MSA, Eldeen MA, Al-Hashem FH, Alkhateeb MA, Alassiri M, Aldera H (2018) Acylated ghrelin protects aorta damage post-MI via activation of eNOS and inhibition of angiotensin-converting enzyme induced activation of NAD(P)H-dependent oxidase. Ultrastruct Pathol 42:416–429
Heineke J, Molkentin JD (2006) Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7:589–600
Shimizu I, Minamino T (2016) Physiological and pathological cardiac hypertrophy. J Mol Cell Cardiol 97:245–262
Nakamura M, Sadoshima J (2018) Mechanisms of physiological and pathological cardiac hypertrophy. Nat Rev Cardiol 15:387–407
Wu R, Chaung WW, Dong W, Ji Y, Barrera R, Nicastro J, Molmenti EP, Coppa GF, Wang P (2012) Ghrelin maintains the cardiovascular stability in severe sepsis. J Surg Res 178:370–377
Soeki T, Koshiba K, Niki T, Kusunose K, Yamaguchi K, Yamada H, Wakatsuki T, Shimabukuro M, Minakuchi K, Kishimoto I, Kangawa K, Sata M (2014) Effect of ghrelin on autonomic activity in healthy volunteers. Peptides 62:1–5
Cauley E, Wang X, Dyavanapalli J, Sun K, Garrott K, Kuzmiak-Glancy S, Kay MW, Mendelowitz D (2015) Neurotransmission to parasympathetic cardiac vagal neurons in the brain stem is altered with left ventricular hypertrophy-induced heart failure. Am J Physiol Heart Circ Physiol 309:H1281–H1287
Tokudome T, Kangawa K (2019) Physiological significance of ghrelin in the cardiovascular system. Proc Jpn Acad, Ser B, Phys Biol Sci 95:459–467
Fan D, Takawale A, Lee J, Kassiri Z (2012) Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair 5:15
Pei XM, Yung BY, Yip SP, Ying M, Benzie IF, Siu PM (2014) Desacyl ghrelin prevents doxorubicin-induced myocardial fibrosis and apoptosis via the GHSR-independent pathway. Am J Physiol Endocrinol Metab 306:E311–E323
Wang X, Wang XL, Chen HL, Wu D, Chen JX, Wang XX, Li RL, He JH, Mo L, Cen X, Wei YQ, Jiang W (2014) Ghrelin inhibits doxorubicin cardiotoxicity by inhibiting excessive autophagy through AMPK and p38-MAPK. Biochem Pharmacol 88:334–350
Nichtova Z, Novotova M, Kralova E, Stankovicova T (2012) Morphological and functional characteristics of models of experimental myocardial injury induced by isoproterenol. Gen Physiol Biophys 31:141–151
Li L, Zhang LK, Pang YZ, Pan CS, Qi YF, Chen L, Wang X, Tang CS, Zhang J (2006) Cardioprotective effects of ghrelin and des-octanoyl ghrelin on myocardial injury induced by isoproterenol in rats. Acta Pharmacol Sin 27:527–535
Xu X, Ding F, Pang J, Gao X, Xu RK, Hao W, Cao JM, Chen C (2012) Chronic administration of hexarelin attenuates cardiac fibrosis in the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 303:H703–H711
Pei XM, Yung BY, Yip SP, Chan LW, Wong CS, Ying M, Siu PM (2015) Protective effects of desacyl ghrelin on diabetic cardiomyopathy. Acta Diabetol 52:293–306
Essick EE, Ouchi N, Wilson RM, Ohashi K, Ghobrial J, Shibata R, Pimentel DR, Sam F (2011) Adiponectin mediates cardioprotection in oxidative stress-induced cardiac myocyte remodeling. Am J Physiol Heart Circ Physiol 301:H984–H993
Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, Pimentel DR, Kumada M, Sato K, Schiekofer S, Ohashi K, Funahashi T, Colucci WS, Walsh K (2004) Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 10:1384–1389
Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Rossi Fanelli F, Schambelan M, Schols A, Schuster M, Thomas D et al (2008) Cachexia: a new definition. Clin Nutr 27:793–799
Levine B, Kalman J, Mayer L, Fillit HM, Packer M (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323:236–241
Dutka DP, Elborn JS, Delamere F, Shale DJ, Morris GK (1993) Tumour necrosis factor alpha in severe congestive cardiac failure. Br Heart J 70:141–143
Doehner W, Frenneaux M, Anker SD (2014) Metabolic impairment in heart failure: the myocardial and systemic perspective. J Am Coll Cardiol 64:1388–1400
Loncar G, Fülster S, von Haehling S, Popovic V (2013) Metabolism and the heart: an overview of muscle, fat, and bone metabolism in heart failure. Int J Cardiol 162:77–85
Bozic B, Loncar G, Prodanovic N, Radojicic Z, Cvorovic V, Dimkovic S, Popovic-Brkic V (2010) Relationship between high circulating adiponectin with bone mineral density and bone metabolism in elderly males with chronic heart failure. J Card Fail 16:301–307
Brink M, Price SR, Chrast J, Bailey JL, Anwar A, Mitch WE, Delafontaine P (2001) Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. Endocrinology 142:1489–1496
Muccioli G, Tsch öp M, Papotti M, Deghenghi R, Heiman M, Ghigo E (2002) Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. Eur J Pharmacol 440:235–254
Schwartz GJ (2000) The role of gastrointestinal vagal afferents in the control of food intake: current prospects. Nutrition 16:866–873
Ueno H, Yamaguchi H, Kangawa K, Nakazato M (2005) Ghrelin: a gastric peptide that regulates food intake and energy homeostasis. Regul Pept 126:11–19
von Haehling S, Anker SD (2015) Treatment of cachexia: an overview of recent developments. Int J Cardiol 184:736–742
Attanasio P, Anker SD, Doehner W, von Haehling S (2011) Hormonal consequences and prognosis of chronic heart failure. Curr Opin Endocrinol Diabetes Obes 18:224–230
Nagaya N, Uematsu M, Kojima M, Date Y, Nakazato M, Okumura H, Hosoda H, Shimizu W, Yamagishi M, Oya H, Koh H, Yutani C, Kangawa K (2001) Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation 104:2034–2038
Nagaya N, Kangawa K (2003) Ghrelin improves left ventricular dysfunction and cardiac cachexia in heart failure. Curr Opin Pharmacol 3:146–151
Nagaya N, Kangawa K (2006) Therapeutic potential of ghrelin in the treatment of heart failure. Drugs 66:439–448
Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, Kennedy AR, Roberts GH, Morgan DG, Ghatei MA, Bloom SR (2000) The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 141:4325–4328
Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S (2001) A role for ghrelin in the central regulation of feeding. Nature 409:194–198
Shintani M, Ogawa Y, Ebihara K, Aizawa-Abe M, Miyanaga F, Takaya K, Hayashi T, Inoue G, Hosoda K, Kojima M, Kangawa K, Nakao K (2001) Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 50:227–232
Palus S, Schur R, Akashi YJ, Bockmeyer B, Datta R, Halem H, Dong J, Culler MD, Adams V, Anker SD, Springer J (2011) Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFbx in a rat heart failure model. PLoS One 6:e26865
Lenk K, Palus S, Schur R, Datta R, Dong J, Culler MD, Anker S, Springer J, Schuler G, Adams V (2013) Effect of ghrelin and its analogues, BIM-28131 and BIM-28125, on the expression of myostatin in a rat heart failure model. J Cachexia Sarcopenia Muscle 4:63–69
Zhang X, Chen C (2012) A new insight of mechanisms, diagnosis and treatment of diabetic cardiomyopathy. Endocrine 41:398–409
Shah S, Thakar CV (2019) Diabetes/kidney/heart disease. Cardiol Clin 37:ix–x
Sezai A, Sekino H, Unosawa S, Taoka M, Osaka S, Tanaka M (2019) Canagliflozin for Japanese patients with chronic heart failure and type II diabetes. Cardiovasc Diabetol 18:76
Dei Cas A, Spigoni V, Ridolfi V, Metra M (2013) Diabetes and chronic heart failure: from diabetic cardiomyopathy to therapeutic approach. Endocr Metab Immune Disord Drug Targets, vol 13:38–50
van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, Kupreishvili K, Ijsselmuiden AJ, Schalkwijk CG, Bronzwaer JG, Diamant M, Borbely A, van der Velden J, Stienen GJ, Laarman GJ, Niessen HW, Paulus WJ (2008) Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117:43–51
Gao WD, Liu Y, Marban E (1996) Selective effects of oxygen free radicals on excitation-contraction coupling in ventricular muscle. Implications for the mechanism of stunned myocardium. Circulation 94:2597–2604
Ma Y, Zhang L, Edwards JN, Launikonis BS, Chen C (2012) Growth hormone secretagogues protect mouse cardiomyocytes from in vitro ischemia/reperfusion injury through regulation of intracellular calcium. PLoS One 7:e35265
Berti F, Muller E, De Gennaro Colonna V, Rossoni G (1998) Hexarelin exhibits protective activity against cardiac ischaemia in hearts from growth hormone-deficient rats. Growth Hormon IGF Res 8(Suppl B):149–152
Frascarelli S, Ghelardoni S, Ronca-Testoni S, Zucchi R (2003) Effect of ghrelin and synthetic growth hormone secretagogues in normal and ischemic rat heart. Basic Res Cardiol 98:401–405
Bisi G, Podio V, Valetto MR, Broglio F, Bertuccio G, Del Rio G, Arvat E, Boghen MF, Deghenghi R, Muccioli G, Ong H, Ghigo E (1999) Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans. J Endocrinol Investig 22:266–272
Zhang X, Qu L, Chen L & Chen C 2018, Improvement of cardiomyocyte function by in vivo hexarelin treatment in streptozotocin-induced diabetic rats, Physiol Rep, vol 6
Broglio F, Arvat E, Benso A, Gottero C, Muccioli G, Papotti M, van der Lely AJ, Deghenghi R, Ghigo E (2001) Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab 86:5083–5086
Lindqvist A, Shcherbina L, Prasad RB, Miskelly MG, Abels M, Martinez-Lopez JA, Fred RG, Nergård BJ, Hedenbro J, Groop L, Hjerling-Leffler J, Wierup N (2020) Ghrelin suppresses insulin secretion in human islets and type 2 diabetes patients have diminished islet ghrelin cell number and lower plasma ghrelin levels. Mol Cell Endocrinol 511:110835
Miegueu P, St Pierre D, Broglio F, Cianflone K (2011) Effect of desacyl ghrelin, obestatin and related peptides on triglyceride storage, metabolism and GHSR signaling in 3T3-L1 adipocytes. J Cell Biochem 112:704–714
Muccioli G, Pons N, Ghe C, Catapano F, Granata R, Ghigo E (2004) Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor. Eur J Pharmacol 498:27–35
Rodriguez A, Gomez-Ambrosi J, Catalan V, Gil MJ, Becerril S, Sainz N, Silva C, Salvador J, Colina I, Fruhbeck G (2009) Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes. Int J Obes 33(p):541–552
van der Lely AJ, Tschöp M, Heiman ML, Ghigo E (2004) Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 25:426–457
Tesauro M, Schinzari F, Caramanti M, Lauro R, Cardillo C (2010) Cardiovascular and metabolic effects of ghrelin. Curr Diabetes Rev 6:228–235
Aragno M, Mastrocola R, Ghe C, Arnoletti E, Bassino E, Alloatti G, Muccioli G (2012) Obestatin induced recovery of myocardial dysfunction in type 1 diabetic rats: underlying mechanisms. Cardiovasc Diabetol 11:129
McLaughlin T, Abbasi F, Lamendola C, Frayo RS, Cummings DE (2004) Plasma ghrelin concentrations are decreased in insulin-resistant obese adults relative to equally obese insulin-sensitive controls. J Clin Endocrinol Metab 89:1630–1635
Tesauro M, Schinzari F, Iantorno M, Rizza S, Melina D, Lauro D, Cardillo C (2005) Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation 112:2986–2992
Gauna C, Meyler FM, Janssen JA, Delhanty PJ, Abribat T, van Koetsveld P, Hofland LJ, Broglio F, Ghigo E, van der Lely AJ (2004) Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. J Clin Endocrinol Metab 89:5035–5042
Giles TD, Materson BJ, Cohn JN, Kostis JB (2009) Definition and classification of hypertension: an update. J Clin Hypertens (Greenwich) 11:611–614
Poykko SM, Kellokoski E, Horkko S, Kauma H, Kesaniemi YA, Ukkola O (2003) Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 52:2546–2553
Poykko S, Ukkola O, Kauma H, Savolainen MJ, Kesaniemi YA (2003) Ghrelin Arg51Gln mutation is a risk factor for type 2 diabetes and hypertension in a random sample of middle-aged subjects. Diabetologia 46:455–458
Yang D, Liu Z, Yang Z (2013) Ghrelin and its relation with N-terminal brain natriuretic peptide, endothelin-1 and nitric oxide in patients with idiopathic pulmonary hypertension. Cardiology 124:241–245
Lin Y, Matsumura K, Fukuhara M, Kagiyama S, Fujii K, Iida M (2004) Ghrelin acts at the nucleus of the solitary tract to decrease arterial pressure in rats. Hypertension 43:977–982
Henriques-Coelho T, Correia-Pinto J, Roncon-Albuquerque R, Baptista MJ, Lourenco AP, Oliveira SM, Brandao-Nogueira A, Teles A, Fortunato JM, Leite-Moreira AF (2004) Endogenous production of ghrelin and beneficial effects of its exogenous administration in monocrotaline-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol 287:H2885–H2890
Makino Y, Hosoda H, Shibata K, Makino I, Kojima M, Kangawa K, Kawarabayashi T (2002) Alteration of plasma ghrelin levels associated with the blood pressure in pregnancy. Hypertension 39:781–784
Raso GM, Bianco G, Iacono A, Esposito E, Autore G, Ferrante MC, Calignano A, Meli R (2007) Maternal adaptations to pregnancy in spontaneously hypertensive rats: leptin and ghrelin evaluation. J Endocrinol 194:611–619
Kalogeris T, Baines CP, Krenz M, Korthuis RJ (2012) Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol 298:229–317
Mao Y, Tokudome T, Kishimoto I (2014) The cardiovascular action of hexarelin. J Geriatr Cardiol, vol 11:253–258
Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R (2014) Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev 66:1142–1174
Raghay K, Akki R, Bensaid D, Errami M (2020) Ghrelin as an anti-inflammatory and protective agent in ischemia/reperfusion injury. Peptides 124:170226
Bukowczan J, Warzecha Z, Ceranowicz P, Kusnierz-Cabala B, Tomaszewska R, Dembinski A (2015) Therapeutic effect of ghrelin in the course of ischemia/reperfusion-induced acute pancreatitis. Curr Pharm Des 21:2284–2290
Qin Y, Li Z, Wang Z, Li Y, Zhao J, Mulholland M, Zhang W (2014) Ghrelin contributes to protection of hepatocellular injury induced by ischaemia/reperfusion. Liver Int 34:567–575
Zhang H, Cui Z, Luo G, Zhang J, Ma T, Hu N, Cui T (2013) Ghrelin attenuates intestinal ischemia/reperfusion injury in mice by activating the mTOR signaling pathway. Int J Mol Med 32:851–859
Zhang Q, Huang C, Meng B, Tang T, Shi Q, Yang H (2012) Acute effect of ghrelin on ischemia/reperfusion injury in the rat spinal cord. Int J Mol Sci 13:9864–9876
Rajan D, Wu R, Shah KG, Jacob A, Coppa GF, Wang P (2012) Human ghrelin protects animals from renal ischemia-reperfusion injury through the vagus nerve. Surgery 151:37–47
Ma Y, Zhang L, Launikonis BS, Chen C (2012) Growth hormone secretagogues preserve the electrophysiological properties of mouse cardiomyocytes isolated from in vitro ischemia/reperfusion heart. Endocrinology 153:5480–5490
Zhang GG, Cai HQ, Li YH, Sui YB, Zhang JS, Chang JR, Ning M, Wu Y, Tang CS, Qi YF, Yin XH (2013) Ghrelin protects heart against ERS-induced injury and apoptosis by activating AMP-activated protein kinase. Peptides 48:156–165
Yuan MJ, Huang H, Tang YH, Wu G, Gu YW, Chen YJ, Huang CX (2011) Effects of ghrelin on Cx43 regulation and electrical remodeling after myocardial infarction in rats. Peptides 32:2357–2361
Soeki T, Niki T, Uematsu E, Bando S, Matsuura T, Kusunose K, Ise T, Ueda Y, Tomita N, Yamaguchi K, Koshiba K, Yagi S, Fukuda D, Taketani Y, Iwase T, Yamada H, Wakatsuki T, Akaike M, Shimabukuro M, Kishimoto I et al (2013) Ghrelin protects the heart against ischemia-induced arrhythmias by preserving connexin-43 protein. Heart Vessel 28:795–801
Camargo-Silva G, Turones LC, da Cruz KR, Gomes KP, Mendonça MM, Nunes A, de Jesus IG, Colugnati DB, Pansani AP, Pobbe RLH, Santos R, Fontes MAP, Guatimosim S, de Castro CH, Ianzer D, Ferreira RN, Xavier CH (2018) Ghrelin potentiates cardiac reactivity to stress by modulating sympathetic control and beta-adrenergic response. Life Sci 196:84–92
Sun HJ, Wu ZY, Nie XW, Bian JS (2019) Role of endothelial dysfunction in cardiovascular diseases: the link between inflammation and hydrogen sulfide. Front Pharmacol 10:1568
Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal MS, Tanaka M, Nozoe S, Hosoda H, Kangawa K, Matsukura S (2002) Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 87:240–244
Nagaya N, Kojima M, Uematsu M, Yamagishi M, Hosoda H, Oya H, Hayashi Y, Kangawa K (2001) Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Phys Regul Integr Comp Phys 280:R1483–R1487
Flammer AJ, Anderson T, Celermajer DS, Creager MA, Deanfield J, Ganz P, Hamburg NM, Lüscher TF, Shechter M, Taddei S, Vita JA, Lerman A (2012) The assessment of endothelial function: from research into clinical practice. Circulation 126:753–767
Matsumura K, Tsuchihashi T, Fujii K, Abe I, Iida M (2002) Central ghrelin modulates sympathetic activity in conscious rabbits. Hypertension 40:694–699
Okumura H, Nagaya N, Enomoto M, Nakagawa E, Oya H, Kangawa K (2002) Vasodilatory effect of ghrelin, an endogenous peptide from the stomach. J Cardiovasc Pharmacol 39:779–783
Wiley KE, Davenport AP (2002) Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1. Br J Pharmacol 136:1146–1152
Iantorno M, Chen H, Kim JA, Tesauro M, Lauro D, Cardillo C, Quon MJ (2007) Ghrelin has novel vascular actions that mimic PI 3-kinase-dependent actions of insulin to stimulate production of NO from endothelial cells. Am J Physiol Endocrinol Metab 292:E756–E764
Shimizu Y, Nagaya N, Teranishi Y, Imazu M, Yamamoto H, Shokawa T, Kangawa K, Kohno N, Yoshizumi M (2003) Ghrelin improves endothelial dysfunction through growth hormone-independent mechanisms in rats. Biochem Biophys Res Commun 310:830–835
Kadoglou NP, Sailer N, Moumtzouoglou A, Kapelouzou A, Tsanikidis H, Vitta I, Karkos C, Karayannacos PE, Gerasimidis T, Liapis CD (2010) Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 118:75–80
Kotani K, Sakane N, Saiga K, Adachi S, Mu H, Kurozawa Y, Kawano M (2006) Serum ghrelin and carotid atherosclerosis in older Japanese people with metabolic syndrome. Arch Med Res 37:903–906
Yano Y, Toshinai K, Inokuchi T, Kangawa K, Shimada K, Kario K, Nakazato M (2009) Plasma des-acyl ghrelin, but not plasma HMW adiponectin, is a useful cardiometabolic marker for predicting atherosclerosis in elderly hypertensive patients. Atherosclerosis 204:590–594
Zhang M, Fang WY, Yuan F, Qu XK, Liu H, Xu YJ, Chen H, Yu YF, Shen Y, Zheng ZC (2012) Plasma ghrelin levels are closely associated with severity and morphology of angiographically-detected coronary atherosclerosis in Chineses patients with diabetes mellitus. Acta Pharmacol Sin 33:452–458
Poykko SM, Kellokoski E, Ukkola O, Kauma H, Paivansalo M, Kesaniemi YA, Horkko S (2006) Plasma ghrelin concentrations are positively associated with carotid artery atherosclerosis in males. J Intern Med 260:43–52
Kim SJ, Paik KH, Kim DI, Choe YH, Kim SW, Jin DK (2010) Correlation between hyperghrelinemia and carotid artery intima-media thickness in children with Prader-Willi syndrome. Yonsei Med J 51:339–344
Laurila M, Santaniemi M, Kesäniemi YA, Ukkola O (2014) High plasma ghrelin protects from coronary heart disease and Leu72Leu polymorphism of ghrelin gene from cancer in healthy adults during the 19 years follow-up study. Peptides 61:122–129
Tahergorabi Z, Rashidi B, Khazaei M (2013) Ghrelin does not alter aortic intima-media thickness and adipose tissue characteristics in control and obese mice. Iran J Basic Med Sci, vol 16:942–945
Ai W, Wu M, Chen L, Jiang B, Mu M, Liu L, Yuan Z (2017) Ghrelin ameliorates atherosclerosis by inhibiting endoplasmic reticulum stress. Fundam Clin Pharmacol 31:147–154
Togliatto G, Trombetta A, Dentelli P, Gallo S, Rosso A, Cotogni P, Granata R, Falcioni R, Delale T, Ghigo E, Brizzi MF (2015) Unacylated ghrelin induces oxidative stress resistance in a glucose intolerance and peripheral artery disease mouse model by restoring endothelial cell miR-126 expression. Diabetes 64:1370–1382
Zhang M, Qu X, Yuan F, Yang Y, Xu L, Dai J, Wang W, Fei J, Hou X, Fang W (2015) Ghrelin receptor deficiency aggravates atherosclerotic plaque instability. Front Biosci (Landmark Ed) 20:604–613
Zhang M, Yuan F, Chen H, Qiu X, Fang W (2007) Effect of exogenous ghrelin on cell differentiation antigen 40 expression in endothelial cells. Acta Biochim Biophys Sin Shanghai 39:974–981
Li WG, Gavrila D, Liu X, Wang L, Gunnlaugsson S, Stoll LL, McCormick ML, Sigmund CD, Tang C, Weintraub NL (2004) Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation 109:2221–2226
Genis BB, Granada ML, Alonso N, Lauzurica R, Jimenez JA, Barluenga E, Homs M, Pastor MC, Salinas I, Quintero JC, Sanmarti A, Romero R (2007) Ghrelin, glucose homeostasis, and carotid intima media thickness in kidney transplantation. Transplantation 84:1248–1254
Wang L, Chen Q, Li G, Ke D (2012) Ghrelin stimulates angiogenesis via GHSR1a-dependent MEK/ERK and PI3K/Akt signal pathways in rat cardiac microvascular endothelial cells. Peptides 33:92–100
Yuan M-J, Hu H-Y, Huang C-X et al (2012) Myocardial angiogenesis after chronic ghrelin treatment in a rat myocardial infarction model. Regul Pept 179:39–42
Wang L, Chen Q, Li G, Ke D (2015) Ghrelin ameliorates impaired angiogenesis of ischemic myocardium through GHSR1a-mediated AMPK/eNOS signal pathway in diabetic rats. Peptides 73:77–87
Katare R, Rawal S, Munasinghe PE, Tsuchimochi H, Inagaki T, Fujii Y, Dixit P, Umetani K, Kangawa K, Shirai M, Schwenke DO (2016) Ghrelin promotes functional angiogenesis in a mouse model of critical limb ischemia through activation of proangiogenic microRNAs. Endocrinology 157:432–445
Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY, Srivastava D (2008) miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 15:272–284
Wang J, He L, Huwatibieke B, Liu L, Lan H, Zhao J, Li Y, Zhang W (2018) Ghrelin stimulates endothelial cells angiogenesis through extracellular regulated protein kinases (ERK) signaling pathway. Int J Mol Sci 19:2530
Mayo LD, Kessler KM, Pincheira R, Warren RS, Donner DB (2001) Vascular endothelial cell growth factor activates CRE-binding protein by signaling through the KDR receptor tyrosine kinase. J Biol Chem 276:25184–25189
Tahergorabi Z, Rashidi B, Khazaei M (2013) Ghrelin does not modulate angiogenesis in matrigel plug in normal and diet-induced obese mice. J Res Med Sci 18:939–942
Tahergorabi Z, Khazaei M, Rashidi B (2015) Systemic administration of ghrelin did not restore angiogenesis in hindlimb ischemia in control and diet-induced obese mice. Bratisl Lek Listy 116:35–40
Khazaei M, Tahergorabi Z (2017) Ghrelin did not change coronary angiogenesis in diet-induced obese mice. Cell Mol Biol (Noisy-le-grand) 63:96–99
Anand S, Majeti BK, Acevedo LM, Murphy EA, Mukthavaram R, Scheppke L, Huang M, Shields DJ, Lindquist JN, Lapinski PE, King PD, Weis SM, Cheresh DA (2010) MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med 16:909–914
Jin W, Reddy MA, Chen Z, Putta S, Lanting L, Kato M, Park JT, Chandra M, Wang C, Tangirala RK, Natarajan R (2012) Small RNA sequencing reveals microRNAs that modulate angiotensin II effects in vascular smooth muscle cells. J Biol Chem 287:15672–15683
Hansen GN, Hansen BL, Jørgensen PN, Scharrer B (1990) Immunocytochemical localization and immunochemical characterization of an insulin-related peptide in the insect Leucophaea maderae. Cell Tissue Res 259:265–273
Stahlhut C, Suárez Y, Lu J, Mishima Y, Giraldez AJ (2012) miR-1 and miR-206 regulate angiogenesis by modulating VegfA expression in zebrafish. Development 139:4356–4364
Stenzel D, Lundkvist A, Sauvaget D, Busse M, Graupera M, van der Flier A, Wijelath ES, Murray J, Sobel M, Costell M, Takahashi S, F ässler R, Yamaguchi Y, Gutmann DH, Hynes RO, Gerhardt H (2011) Integrin-dependent and -independent functions of astrocytic fibronectin in retinal angiogenesis. Development 138:4451–4463
Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, Goto D, Takeshita A (2007) Characteristics and outcomes of patients with heart failure in general practices and hospitals. Circ J 71:449–454
Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, ODonnell C, Roger V, Sorlie P et al (2008) Heart disease and stroke statistics–2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117:25–146
Zhang G, Yin X, Qi Y, Pendyala L, Chen J, Hou D, Tang C (2010) Ghrelin and cardiovascular diseases. Curr Cardiol Rev 6:62–70
Mao Y, Tokudome T, Kishimoto I (2014) Ghrelin as a treatment for cardiovascular diseases. Hypertension 64:450–454
Nagaya N, Miyatake K, Uematsu M, Oya H, Shimizu W, Hosoda H, Kojima M, Nakanishi N, Mori H, Kangawa K (2001) Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with chronic heart failure. J Clin Endocrinol Metab 86:5854–5859
Ashby D, Choi P, Bloom S (2008) Gut hormones and the treatment of disease cachexia. Proc Nutr Soc 67:263–269
Xin X, Ren AJ, Zheng X, Qin YW, Zhao XX, Yuan WJ, Guo ZF (2009) Disturbance of circulating ghrelin and obestatin in chronic heart failure patients especially in those with cachexia. Peptides 30:2281–2285
Mitacchione G, Powers JC, Grifoni G, Woitek F, Lam A, Ly L, Settanni F, Makarewich CA, McCormick R, Trovato L, Houser SR, Granata R, Recchia FA (2014) The gut hormone ghrelin partially reverses energy substrate metabolic alterations in the failing heart. Circ Heart Fail 7:643–651
Enomoto M, Nagaya N, Uematsu M, Okumura H, Nakagawa E, Ono F, Hosoda H, Oya H, Kojima M, Kanmatsuse K, Kangawa K (2003) Cardiovascular and hormonal effects of subcutaneous administration of ghrelin, a novel growth hormone-releasing peptide, in healthy humans. Clin Sci 105:431–435
Schiattarella GG, Hill JA (2016) Therapeutic targeting of autophagy in cardiovascular disease. J Mol Cell Cardiol 95:86–93
Sciarretta S, Maejima Y, Zablocki D, Sadoshima J (2018) The role of autophagy in the heart. Annu Rev Physiol 80:1–26
Xu M, Liu L, Song C, Chen W, Gui S (2017) Ghrelin improves vascular autophagy in rats with vascular calcification. Life Sci 179:23–29
Godar RJ, Ma X, Liu H, Murphy JT, Weinheimer CJ, Kovacs A, Crosby SD, Saftig P, Diwan A (2015) Repetitive stimulation of autophagy-lysosome machinery by intermittent fasting preconditions the myocardium to ischemia-reperfusion injury. Autophagy 11:1537–1560
Zhang S, Mao Y, Fan X (2018) Inhibition of ghrelin o-acyltransferase attenuated lipotoxicity by inducing autophagy via AMPK-mTOR pathway. Drug Des Devel Ther 12:873–885
Mao Y, Cheng J, Yu F, Li H, Guo C, Fan X (2015) Ghrelin attenuated lipotoxicity via autophagy induction and nuclear factor-κB inhibition. Cell Physiol Biochem 37:563–576
Yuan MJ, Wang T (2020) The new mechanism of ghrelin/GHSR-1a on autophagy regulation. Peptides, vol 126:170264
Andres AM, Kooren JA, Parker SJ, Tucker KC, Ravindran N, Ito BR, Huang C, Venkatraman V, Van Eyk JE, Gottlieb RA, Mentzer RM (2016) Discordant signaling and autophagy response to fasting in hearts of obese mice: implications for ischemia tolerance. Am J Physiol Heart Circ Physiol 311:H219–H228
Toshinai K, Mondal MS, Nakazato M, Date Y, Murakami N, Kojima M, Kangawa K, Matsukura S (2001) Upregulation of ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration. Biochem Biophys Res Commun 281:1220–1225
Agbo E, Li MX, Wang YQ, Saahene RO, Massaro J, Tian GZ (2019) Hexarelin protects cardiac H9C2 cells from angiotensin II-induced hypertrophy via the regulation of autophagy. Pharmazie 74:485–491
Tong XX, Wu D, Wang X, Chen HL, Chen JX, Wang XX, Wang XL, Gan L, Guo ZY, Shi GX, Zhang YZ, Jiang W (2012) Ghrelin protects against cobalt chloride-induced hypoxic injury in cardiac H9c2 cells by inhibiting oxidative stress and inducing autophagy. Peptides 38:217–227
Kola B, Hubina E, Tucci SA, Kirkham TC, Garcia EA, Mitchell SE, Williams LM, Hawley SA, Hardie DG, Grossman AB, Korbonits M (2005) Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 280:25196–25201
Mihaylova MM, Shaw RJ (2011) The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 13:1016–1023
Sun Q, Zang WJ, Chen C (2010) Growth hormone secretagogues reduce transient outward K+ current via phospholipase C/protein kinase C signaling pathway in rat ventricular myocytes. Endocrinology 151:1228–1235
Bedendi I, Alloatti G, Marcantoni A, Malan D, Catapano F, Ghe C, Deghenghi R, Ghigo E, Muccioli G (2003) Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des-Gln14-ghrelin. Eur J Pharmacol 476:87–95
Bedendi I, Gallo MP, Malan D, Levi RC, Alloatti G (2001) Role of endothelial cells in modulation of contractility induced by hexarelin in rat ventricle. Life Sci 69:2189–2201
Cao CM, Xia Q, Gao Q, Chen M, Wong TM (2005) Calcium-activated potassium channel triggers cardioprotection of ischemic preconditioning. J Pharmacol Exp Ther 312:644–650
Xu W, Liu Y, Wang S, McDonald T, Van Eyk JE, Sidor A, ORourke B (2002) Cytoprotective role of Ca2+- activated K+ channels in the cardiac inner mitochondrial membrane. Science 298:1029–1033
Xu Y, Tuteja D, Zhang Z, Xu D, Zhang Y, Rodriguez J, Nie L, Tuxson HR, Young JN, Glatter KA, Vázquez AE, Yamoah EN, Chiamvimonvat N (2003) Molecular identification and functional roles of a Ca(2+)-activated K+ channel in human and mouse hearts. J Biol Chem 278:49085–49094
Casis O, Iriarte M, Gallego M, Sanchez-Chapula JA (1998) Differences in regional distribution of K+ current densities in rat ventricle. Life Sci 63:391–400
Greenstein JL, Wu R, Po S, Tomaselli GF, Winslow RL (2000) Role of the calcium-independent transient outward current I(to1) in shaping action potential morphology and duration. Circ Res 87:1026–1033
Xu XB, Cao JM, Pang JJ, Xu RK, Ni C, Zhu WL, Asotra K, Chen MC, Chen C (2003) The positive inotropic and calcium-mobilizing effects of growth hormone-releasing peptides on rat heart. Endocrinology 144:5050–5057
Soares JB, Rocha-Sousa A, Castro-Chaves P, Henriques-Coelho T, Leite-Moreira AF (2006) Inotropic and lusitropic effects of ghrelin and their modulation by the endocardial endothelium, NO, prostaglandins, GHS-R1a and KCa channels. Peptides 27:1616–1623
Soares JB, Rocha-Sousa A, Castro-Chaves P, Henriques-Coelho T, Lourenco AP, Roncon-Albuquerque R, Leite-Moreira AF (2005) Contractile effects of ghrelin and expression of its receptor GHS-R1a in normal and hypertrophic myocardium. Rev Port Cardiol 24:1235–1242
Mustafa ER, Lopez Soto EJ, Martinez Damonte V, Rodriguez SS, Lipscombe D, Raingo J (2017) Constitutive activity of the ghrelin receptor reduces surface expression of voltage-gated Ca2+ channels in a CaVβ-dependent manner. J Cell Sci 130:3907–3917
Warbrick I, Rabkin SW (2019) Effect of the peptides relaxin, neuregulin, ghrelin and glucagon-like peptide-1, on cardiomyocyte factors involved in the molecular mechanisms leading to diastolic dysfunction and/or heart failure with preserved ejection fraction. Peptides 111:33–41
Sun Q, Ma Y, Zhang L, Zhao YF, Zang WJ, Chen C (2010) Effects of GH secretagogues on contractility and Ca2+ homeostasis of isolated adult rat ventricular myocytes. Endocrinology 151:4446–4454
Pettersson I, Muccioli G, Granata R, Deghenghi R, Ghigo E, Ohlsson C, Isgaard J (2002) Natural (ghrelin) and synthetic (hexarelin) GH secretagogues stimulate H9c2 cardiomyocyte cell proliferation. J Endocrinol 175:201–209
Pierno S, De Luca A, Desaphy JF, Fraysse B, Liantonio A, Didonna MP, Lograno M, Cocchi D, Smith RG, Camerino DC (2003) Growth hormone secretagogues modulate the electrical and contractile properties of rat skeletal muscle through a ghrelin-specific receptor. Br J Pharmacol 139:575–584
Shinde UA, Desai KM, Yu C, Gopalakrishnan V (2005) Nitric oxide synthase inhibition exaggerates the hypotensive response to ghrelin: role of calcium-activated potassium channels. J Hypertens 23:779–784
Granata R, Settanni F, Biancone L, Trovato L, Nano R, Bertuzzi F, Destefanis S, Annunziata M, Martinetti M, Catapano F, Ghè C, Isgaard J, Papotti M, Ghigo E, Muccioli G (2007) Acylated and unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic beta-cells and human islets: involvement of 3,5-cyclic adenosine monophosphate/protein kinase A, extracellular signal-regulated kinase 1/2, and phosphatidyl inositol 3-kinase/Akt signaling. Endocrinology 148:512–529
Iglesias MJ, Pineiro R, Blanco M, Gallego R, Dieguez C, Gualillo O, Gonzalez-Juanatey JR, Lago F (2004) Growth hormone releasing peptide (ghrelin) is synthesized and secreted by cardiomyocytes. Cardiovasc Res 62:481–488
Shati AA, El-Kott AF (2019) Acylated ghrelin prevents doxorubicin-induced cardiac intrinsic cell death and fibrosis in rats by restoring IL-6/JAK2/STAT3 signaling pathway and inhibition of STAT1. Naunyn Schmiedeberg's Arch Pharmacol 392(p):1151–1168
Xu Z, Lin S, Wu W, Tan H, Wang Z, Cheng C, Lu L, Zhang X (2008) Ghrelin prevents doxorubicin-induced cardiotoxicity through TNF-alpha/NF-kappaB pathways and mitochondrial protective mechanisms. Toxicology 247:133–138
Gupta S, Kass GE, Szegezdi E, Joseph B (2009) The mitochondrial death pathway: a promising therapeutic target in diseases. J Cell Mol Med 13:1004–1033
Zhang GG, Teng X, Liu Y, Cai Y, Zhou YB, Duan XH, Song JQ, Shi Y, Tang CS, Yin XH, Qi YF (2009) Inhibition of endoplasm reticulum stress by ghrelin protects against ischemia/reperfusion injury in rat heart. Peptides 30:1109–1116
Melnikova NP, Timoshin SS, Jivotova EY, Pelliniemi LJ, Jokinen E, Abdelwahid E (2006) Angiotensin-II activates apoptosis, proliferation and protein synthesis in the left heart ventricle of newborn albino rats. Int J Cardiol 112:219–222
Alloatti G, Arnoletti E, Bassino E, Penna C, Perrelli MG, Ghé C, Muccioli G (2010) Obestatin affords cardioprotection to the ischemic-reperfused isolated rat heart and inhibits apoptosis in cultures of similarly stressed cardiomyocytes. Am J Physiol Heart Circ Physiol 299:H470–H481
Wang X, Yang C, Liu X, Yang P (2018) Ghrelin alleviates angiotensin II-induced H9c2 apoptosis: impact of the miR-208 family. Med Sci Monit 24:6707–6716
Dixit VD, Schaffer EM, Pyle RS, Collins GD, Sakthivel SK, Palaniappan R, Lillard JW, Taub DD (2004) Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 114:57–66
Wang L, Saint-Pierre DH, Taché Y (2002) Peripheral ghrelin selectively increases Fos expression in neuropeptide Y - synthesizing neurons in mouse hypothalamic arcuate nucleus. Neurosci Lett 325:47–51
Banks WA, Tschöp M, Robinson SM, Heiman ML (2002) Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure. J Pharmacol Exp Ther 302:822–827
Tsubota Y, Owada-Makabe K, Yukawa K, Maeda M (2005) Hypotensive effect of des-acyl ghrelin at nucleus tractus solitarii of rat. Neuroreport 16:163–166
Vlasova MA, Järvinen K, Herzig KH (2009) Cardiovascular effects of ghrelin antagonist in conscious rats. Regul Pept 156:72–76
Shimizu S, Akiyama T, Kawada T, Sonobe T, Kamiya A, Shishido T, Tokudome T, Hosoda H, Shirai M, Kangawa K, Sugimachi M (2011) Centrally administered ghrelin activates cardiac vagal nerve in anesthetized rabbits. Auton Neurosci 162:60–65
Serra-Prat M, Fernandez X, Burdoy E, Mussoll J, Casamitjana R, Puig-Domingo M (2007) The role of ghrelin in the energy homeostasis of elderly people: a population-based study. J Endocrinol Investig 30:484–490
Nass R, Farhy LS, Liu J, Pezzoli SS, Johnson ML, Gaylinn BD, Thorner MO (2014) Age-dependent decline in acyl-ghrelin concentrations and reduced association of acyl-ghrelin and growth hormone in healthy older adults. J Clin Endocrinol Metab 99:602–608
Yin Y, Zhang W (2016) The role of ghrelin in senescence: a mini-review. Gerontology 62:155–162
Kozakowski J, Rabijewski M, Zgliczynski W (2008) Ghrelin - growth hormone releasing and orexigenic hormone in men declines with age, insulin and with decrease in testosterone concentration. Neuro Endocrinol Lett 29(p):100–106
Rigamonti AE, Pincelli AI, Corra B, Viarengo R, Bonomo SM, Galimberti D, Scacchi M, Scarpini E, Cavagnini F, Muller EE (2002) Plasma ghrelin concentrations in elderly subjects: comparison with anorexic and obese patients. J Endocrinol 175:1–5
Sturm K, MacIntosh CG, Parker BA, Wishart J, Horowitz M, Chapman IM (2003) Appetite, food intake, and plasma concentrations of cholecystokinin, ghrelin, and other gastrointestinal hormones in undernourished older women and well-nourished young and older women. J Clin Endocrinol Metab 88:3747–3755
Yano Y, Nakazato M, Toshinai K, Inokuchi T, Matsuda S, Hidaka T, Hayakawa M, Kangawa K, Shimada K, Kario K (2014) Circulating des-acyl ghrelin improves cardiovascular risk prediction in older hypertensive patients. Am J Hypertens 27:727–733
Liu YL, Yakar S, Otero-Corchon V, Low MJ, Liu JL (2002) Ghrelin gene expression is age-dependent and influenced by gender and the level of circulating IGF-I. Mol Cell Endocrinol 189:97–103
Wolden-Hanson T (2006) Mechanisms of the anorexia of aging in the Brown Norway rat. Physiol Behav 88:267–276
Kappeler L, Zizzari P, Alliot J, Epelbaum J, Bluet-Pajot MT (2004) Delayed age-associated decrease in growth hormone pulsatile secretion and increased orexigenic peptide expression in the Lou C/JaLL rat. Neuroendocrinology 80:273–283
Akimoto Y, Kanai S, Ohta M, Akimoto S, Uematsu H, Miyasaka K (2012) Age-associated reduction of stimulatory effect of ghrelin on food intake in mice. Arch Gerontol Geriatr 55:238–243
Sun Y, Garcia JM, Smith RG (2007) Ghrelin and growth hormone secretagogue receptor expression in mice during aging. Endocrinology 148:1323–1329
Fujitsuka N, Asakawa A, Morinaga A, Amitani MS, Amitani H, Katsuura G, Sawada Y, Sudo Y, Uezono Y, Mochiki E, Sakata I, Sakai T, Hanazaki K, Yada T, Yakabi K, Sakuma E, Ueki T, Niijima A, Nakagawa K, Okubo N et al (2016) Increased ghrelin signaling prolongs survival in mouse models of human aging through activation of sirtuin1. Mol Psychiatry 21:1613–1623
North BJ, Sinclair DA (2012) The intersection between aging and cardiovascular disease. Circ Res 110:1097–1108
Sullivan R, Randhawa VK, Stokes A, Wu D, Lalonde T, Kiaii B, Luyt L, Wisenberg G, Dhanvantari S (2019) Dynamics of the ghrelin/growth hormone secretagogue receptor system in the human heart before and after cardiac transplantation. Journal of the Endocrine Society 3:748–762
Wren AM, Seal LJ, Cohen MA et al (2001) Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86:5992
Trippel TD, Holzendorf V, Halle M, Gelbrich G, Nolte K, Duvinage A, Schwarz S, Rutscher T, Wiora J, Wachter R, Herrmann-Lingen C (2017) Ghrelin and hormonal markers under exercise training in patients with heart failure with preserved ejection fraction: results from the Ex-DHF pilot study. ESC Heart Failure 4:56–65
Tesauro M, Schinzari F, Rovella V, Di Daniele N, Lauro D, Mores N, Veneziani A, Cardillo C (2009) Ghrelin restores the endothelin 1/nitric oxide balance in patients with obesity-related metabolic syndrome. Hypertension 54:995–1000
Togliatto G, Trombetta A, Dentelli P, Baragli A, Rosso A, Granata R, Ghigo D, Pegoraro L, Ghigo E, Brizzi MF (2010) Unacylated ghrelin rescues endothelial progenitor cell function in individuals with type 2 diabetes. Diabetes 59:1016–1025
Author information
Authors and Affiliations
Contributions
SG conceived the idea and prepared the manuscript as well as the figures. AM edited the draft manuscript and checked and arranged the references. Both the authors approved the final version of the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Gupta, S., Mitra, A. Heal the heart through gut (hormone) ghrelin: a potential player to combat heart failure. Heart Fail Rev 26, 417–435 (2021). https://doi.org/10.1007/s10741-020-10032-2
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10741-020-10032-2